Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3

BACKGROUND: Long QT syndrome type 3 (LQT3) is a lethal disease caused by gain-of-function mutations in the SCN5A gene, coding for the alpha-subunit of the sodium channel NaV1.5. Mexiletine is used to block late sodium current and to shorten QT interval in LQT3 patients. OBJECTIVES: The aim of this s...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazzanti, Andrea, Maragna, Riccardo, Faragli, Alessandro, Monteforte, Nicola, Bloise, Raffaella, Memmi, Mirella, Novelli, Valeria, Baiardi, Paola, Bagnardi, Vincenzo, Etheridge, Susan P., Napolitano, Carlo, Priori, Silvia G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Biomedical 2016
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773513/
https://www.ncbi.nlm.nih.gov/pubmed/26940925
http://dx.doi.org/10.1016/j.jacc.2015.12.033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773513/
https://www.ncbi.nlm.nih.gov/pubmed/26940925
http://dx.doi.org/10.1016/j.jacc.2015.12.033

Ejemplares similares